[A program to detect deficient quality of commercialized drugs].
Defective drugs have been found during the postmarketing phase in various countries, regardless of those nations' level of economic development. This paper proposes guidelines for a program to uncover drug defects in the postmarketing surveillance period. Such a program should be run by a center or service organized for that purpose within the framework of a national drug surveillance system.
D003906:Developing Countries; D016568:Drugs, Generic / Q000592:standards*; D007843:Latin America; D004366:Nonprescription Drugs / Q000592:standards*; D011785:Quality Assurance, Health Care; D014944:World Health Organization
D016568:Drugs, Generic; D004366:Nonprescription Drugs